CO2018011408A2 - Compuestos de pirimidina como inhibidores de la quinasa jak - Google Patents

Compuestos de pirimidina como inhibidores de la quinasa jak

Info

Publication number
CO2018011408A2
CO2018011408A2 CONC2018/0011408A CO2018011408A CO2018011408A2 CO 2018011408 A2 CO2018011408 A2 CO 2018011408A2 CO 2018011408 A CO2018011408 A CO 2018011408A CO 2018011408 A2 CO2018011408 A2 CO 2018011408A2
Authority
CO
Colombia
Prior art keywords
compounds
inhibitors
pyrimidine compounds
jak kinase
provides
Prior art date
Application number
CONC2018/0011408A
Other languages
English (en)
Spanish (es)
Inventor
Anne-Marie Beausoleil
Ryan Hudson
Jennifer Kozak
Melissa Fleury
Paul R Fatheree
Dante D Podesto
Xiaojun Huang
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CO2018011408A2 publication Critical patent/CO2018011408A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2018/0011408A 2016-04-28 2018-10-25 Compuestos de pirimidina como inhibidores de la quinasa jak CO2018011408A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328737P 2016-04-28 2016-04-28
PCT/US2017/029796 WO2017189822A1 (en) 2016-04-28 2017-04-27 Pyrimidine compounds as jak kinase inhibitors

Publications (1)

Publication Number Publication Date
CO2018011408A2 true CO2018011408A2 (es) 2018-11-13

Family

ID=58672793

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0011408A CO2018011408A2 (es) 2016-04-28 2018-10-25 Compuestos de pirimidina como inhibidores de la quinasa jak

Country Status (20)

Country Link
US (3) US10028960B2 (https=)
EP (1) EP3433253B1 (https=)
JP (1) JP6881879B2 (https=)
KR (1) KR102244257B1 (https=)
CN (1) CN109071529B (https=)
AU (1) AU2017258186B2 (https=)
BR (1) BR112018072168A2 (https=)
CA (1) CA3020506A1 (https=)
CL (1) CL2018003060A1 (https=)
CO (1) CO2018011408A2 (https=)
DK (1) DK3433253T3 (https=)
EA (1) EA035226B1 (https=)
ES (1) ES2779880T3 (https=)
IL (1) IL262386B (https=)
MX (1) MX377180B (https=)
PT (1) PT3433253T (https=)
SG (1) SG11201809342YA (https=)
TW (1) TWI726094B (https=)
WO (1) WO2017189822A1 (https=)
ZA (1) ZA201807179B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6692836B2 (ja) 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのナフチリジン化合物
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
MX377180B (es) 2016-04-28 2025-03-07 Theravance Biopharma R&D Ip Llc Compuestos de pirimidina como inhibidores de la quinasa jak.
HRP20221221T1 (hr) * 2017-10-27 2022-12-09 Theravance Biopharma R&D Ip, Llc Pirimidinski spoj kao inhibitor jak kinaze
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2020108516A1 (zh) * 2018-11-27 2020-06-04 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
JP2022510980A (ja) * 2018-11-30 2022-01-28 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ヘテロ芳香族誘導体調節因子、その製造方法及び使用
EP3958969B1 (en) * 2019-04-24 2024-01-10 Theravance Biopharma R&D IP, LLC Ester and carbonate pyrimidine compounds as jak kinase inhibitors
TW202106681A (zh) * 2019-04-24 2021-02-16 美商施萬生物製藥研發Ip有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
TW202207918A (zh) * 2020-05-14 2022-03-01 美商施萬生物製藥研發Ip有限責任公司 腸道選擇性jak3抑制劑的投與
WO2022076703A1 (en) * 2020-10-09 2022-04-14 Janssen Biotech, Inc. Processes for preparing a pan-jak inhibitor and related intermediate compounds
WO2022083687A1 (zh) * 2020-10-21 2022-04-28 南京明德新药研发有限公司 硒杂环类化合物及其应用
WO2023011359A1 (zh) * 2021-08-05 2023-02-09 南京明德新药研发有限公司 桥环类化合物及其应用
CN113883920B (zh) * 2021-10-25 2024-01-23 安徽华铂再生资源科技有限公司 一种降低空分装置空冷塔出口温度的方法
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用
WO2025040148A1 (zh) * 2023-08-22 2025-02-27 北京普祺医药科技股份有限公司 一种用于jak抑制剂的外用凝胶及其用途
TW202515852A (zh) * 2023-09-15 2025-04-16 美商莫菲克醫療股份有限公司 抑制人類整合素α4β7

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
AU2005322855B2 (en) * 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CA2629781A1 (en) 2005-11-16 2007-05-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP2009541480A (ja) 2006-06-30 2009-11-26 アストラゼネカ アクチボラグ 癌の治療において有用なピリミジン誘導体
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
BR112014015549A8 (pt) 2011-12-22 2017-07-04 Hoffmann La Roche composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (https=) * 2014-08-21 2018-03-31
JP6692836B2 (ja) 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのナフチリジン化合物
MX377180B (es) * 2016-04-28 2025-03-07 Theravance Biopharma R&D Ip Llc Compuestos de pirimidina como inhibidores de la quinasa jak.

Also Published As

Publication number Publication date
US20180303836A1 (en) 2018-10-25
US20200046709A1 (en) 2020-02-13
US10028960B2 (en) 2018-07-24
CA3020506A1 (en) 2017-11-02
KR102244257B1 (ko) 2021-04-26
KR20190002591A (ko) 2019-01-08
JP2019514903A (ja) 2019-06-06
ZA201807179B (en) 2019-08-28
US20170312280A1 (en) 2017-11-02
IL262386B (en) 2021-08-31
EA035226B1 (ru) 2020-05-19
ES2779880T3 (es) 2020-08-20
MX2018013191A (es) 2019-02-13
US10485803B2 (en) 2019-11-26
AU2017258186A1 (en) 2018-11-15
CL2018003060A1 (es) 2018-12-14
MX377180B (es) 2025-03-07
CN109071529A (zh) 2018-12-21
TWI726094B (zh) 2021-05-01
EP3433253A1 (en) 2019-01-30
EP3433253B1 (en) 2020-02-12
WO2017189822A1 (en) 2017-11-02
BR112018072168A2 (pt) 2019-02-12
TW201739747A (zh) 2017-11-16
EA201892436A1 (ru) 2019-04-30
PT3433253T (pt) 2020-04-30
CN109071529B (zh) 2021-08-06
US11110095B2 (en) 2021-09-07
AU2017258186B2 (en) 2020-09-17
JP6881879B2 (ja) 2021-06-02
DK3433253T3 (da) 2020-04-06
SG11201809342YA (en) 2018-11-29
IL262386A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CO2020001469A2 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
EA201691302A1 (ru) Новые гетероциклические соединения
MX385082B (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam